» Articles » PMID: 35367478

The Janus of Protein Corona on Nanoparticles for Tumor Targeting, Immunotherapy and Diagnosis

Overview
Specialty Pharmacology
Date 2022 Apr 3
PMID 35367478
Authors
Affiliations
Soon will be listed here.
Abstract

The therapeutics based on nanoparticles (NPs) are considered as the promising strategy for tumor detection and treatment. However, one of the most challenges is the adsorption of biomolecules on NPs after their exposition to biological medium, leading unpredictable in vivo behaviors. The interactions caused by protein corona (PC) will influence the biological fate of NPs in either negative or positive ways, including (i) blood circulation, accumulation and penetration of NPs at targeting sites, and further cellular uptake in tumor targeting delivery; (ii) interactions between NPs and receptors on immune cells for immunotherapy. Besides, PC on NPs could be utilized as new biomarker in tumor diagnosis by identifying the minor change of protein concentration led by tumor growth and invasion in blood. Herein, the mechanisms of these PC-mediated effects will be introduced. Moreover, the recent advances about the strategies will be reviewed to reduce negative effects caused by PC and/or utilize positive effects of PC on tumor targeting, immunotherapy and diagnosis, aiming to provide a reasonable perspective to recognize PC with their applications.

Citing Articles

Biogenic nanoparticles as a promising drug delivery system.

Abdel-Megeed R Toxicol Rep. 2025; 14:101887.

PMID: 39867515 PMC: 11762933. DOI: 10.1016/j.toxrep.2024.101887.


Boosting Lipofection Efficiency Through Enhanced Membrane Fusion Mechanisms.

Pavlov R, Akimov S, Dashinimaev E, Bashkirov P Int J Mol Sci. 2025; 25(24.

PMID: 39769303 PMC: 11677079. DOI: 10.3390/ijms252413540.


The Protein Corona on Nanoparticles for Tumor Targeting in Prostate Cancer-A Review of the Literature and Experimental Trial Protocol.

Bevilacqua G, Corvino R, Capriotti A, Montone C, Moriconi M, Salciccia S Biology (Basel). 2025; 13(12.

PMID: 39765691 PMC: 11672965. DOI: 10.3390/biology13121024.


Specific surface-modified iron oxide nanoparticles trigger complement-dependent innate and adaptive antileukaemia immunity.

Li Y, Wu W, Liu Q, Wu Q, Ren P, Xi X Nat Commun. 2024; 15(1):10400.

PMID: 39613769 PMC: 11607078. DOI: 10.1038/s41467-024-54810-0.


Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects.

Liu Y, Li Y, Shen W, Li M, Wang W, Jin X Front Pharmacol. 2024; 15:1409163.

PMID: 39070787 PMC: 11272567. DOI: 10.3389/fphar.2024.1409163.